HB5747, titled the Preventing Illegal Laboratories and Protecting Public Health Act of 2025, would create a federal program to track transfers of certain highly pathogenic agents and strengthen oversight of high-containment laboratories. The bill directs the Secretary of Health and Human Services, through the Administration for Strategic Preparedness and Response, to maintain a list of covered agents and require distributors to keep electronic logbooks of sales, leases, loans, and other transfers. Those logbooks would capture purchaser identity and contact information, intended use, storage location, transfer details, and purchaser signatures, and distributors would have to verify identification before completing a transfer. The bill also requires retention of records for at least three years and limits disclosure of logbook information to specified public health, law enforcement, and national security purposes, while exempting the records from FOIA.
In addition to the transfer-log requirements, the bill would direct the National Security Advisor to identify a single federal entity to conduct periodic strategic evaluations of high-containment laboratories in the United States. Those evaluations would assess the number, location, mission, security, risks, and oversight needs of such labs, and would be paired with development of updated national standards for their design, construction, operation, and maintenance. The bill also calls for a federal Public Health Biosafety and Biosecurity Team to serve as a single point of contact for state, local, tribal, and territorial governments, and it requires a feasibility study on creating a database of existing high-containment laboratories.
The bill would affect federal public health, biosafety, biosecurity, and national security oversight rather than state law directly. It would add new federal compliance obligations for entities that distribute highly pathogenic agents, including public repositories and biobanks, and would create new recordkeeping, identity-verification, and reporting expectations. It also expressly preserves existing federal select agent laws, indicating that the new requirements are intended to supplement, not replace, current regulation of select agents and toxins.
The available context shows no recorded votes or committee debate, so there is no documented partisan or stakeholder sentiment in the materials provided. Based on the bill text, the measure appears to be framed as a public health and security initiative aimed at preventing illegal or unsafe laboratory activity and improving federal coordination. The absence of transcripts means there is no direct evidence of support or opposition from committee members, agencies, or outside groups in the provided record.
The main points of potential contention are likely to be the scope of federal oversight, the burden on distributors and research repositories, and privacy or confidentiality concerns around the logbooks and laboratory database. The bill requires detailed purchaser information, mandates identity checks, and authorizes broad but controlled access for government entities, which could raise concerns about administrative burden, sensitive business information, and data security. Another possible issue is the breadth of the laboratory evaluation and database provisions, which could be viewed as necessary transparency and preparedness measures by supporters, but as intrusive or duplicative by critics.
The bill would create new federal requirements for distributors of covered highly pathogenic agents, including electronic logbook maintenance, purchaser identification verification, retention of transaction records, and limits on disclosure of those records. It would also require HHS to maintain and update a list of covered agents, and it would establish a federal process for evaluating high-containment laboratories, setting national standards, creating a biosafety/biosecurity contact team, and studying a national laboratory database. The bill expressly states that it does not supersede the Federal Select Agent Program under existing public health and agricultural bioterrorism laws.
The provided record contains no committee transcript and no vote history, so there is no documented formal sentiment from lawmakers in the materials. The bill’s structure and title suggest a generally protective, public-safety-oriented purpose focused on biosafety, biosecurity, and preventing illegal laboratory activity. On its face, the measure appears designed to appeal to concerns about public health preparedness and national security, but the absence of debate means support and opposition cannot be measured from the record provided.
Likely areas of contention include the administrative and compliance burden on covered distributors, biobanks, and public repositories that would have to collect and retain detailed purchaser information and verify identities before transfers. Privacy and confidentiality concerns may also arise from the required logbooks and the proposed laboratory database, even though the bill restricts disclosure and exempts logbooks from FOIA. A further point of debate could be whether the bill duplicates or overlaps existing federal select agent oversight, or whether the new reporting and evaluation framework is necessary to close biosafety and biosecurity gaps.